课题基金 / 基金详情

Highly active anti-retroviral therapy use during pregnancy and the risk of mother-to-child transmission, congenital malformation, and neonatal death

Highly active anti-retroviral therapy use during pregnancy and the risk of mother-to-child transmission, congenital malformation, and neonatal death
怀孕期间使用高效抗逆转录病毒治疗会增加母婴传播、先天畸形和新生儿死亡的风险
批准号：
288921
负责人：
Brard Anick
金额：
$7.29万
依托单位：
Centre hospitalier universitaire Sainte-Justine (Montral, Qubec)
依托单位国家：
加拿大
项目类别：
Miscellaneous Programs
财政年份：
2013
资助国家：
加拿大
项目状态：
已结题
起止时间：
2013-06-01 至 2014-06-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=288921&lang=en
关键词：
Haart Use Major Congenital Malformations Mother To Child Transmission Neonatal Death Pregnancy

项目摘要

项目成果

Brard Anick的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Present data suggest that pregnant HIV women should be treated during gestation to prevent MCTC and neonatal death. However, there is no consensus as to whether treatment should be initiated in the first trimester (when organogenesis occurs) or later (whe
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The CAnadian Mother-Child Initiative - knowledge mobilization from COnception to adulthood - CAMCCO-Outreach.
The CAnadian Mother-ChIld COLlaborative Training Platform - The CAMCCO-L Training Platform - SPOR Supplement
Canada Research Chair - Tier 1
  • 批准号：
    454003
  • 项目类别：
  • 资助金额：
    $101.99万
  • 财政年份：
    2021
  • 负责人：
    Brard Anick
  • 依托单位：
    Universit de Montral
The CAnadian Mother-ChIld COLlaborative Training Platform - The CAMCCO-L Training Platform
海外基金